Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 4/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.77 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.77 |
| ▸ | DRD1 | P21728 | 2/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.77 |
| ▸ | HTR2B | P41595 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.77 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.77 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CES1 | P23141 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403893 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL30277249 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL233523 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL3173500 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL364610 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL19148650 | 1.00 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Water SCHEMBL3377943 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL6635560 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Bromide SCHEMBL1130039 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Iodide SCHEMBL1402210 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 48886 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260140098-A1 | METHOD FOR TREATING PLASMA SAMPLE CONTAINING (7aS,2'S)-2-OXO-CLOPIDOGREL AND METHOD FOR DETERMINING THE SAME | CHENGDU SHIBEIKANG BIOMEDICAL TECH CO LTD (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| WO-2026098615-A1 | COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF IN PREPARATION OF DRUGS FOR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES | 上海东西智荟生物医药有限公司 | 2026-05-15 | — | — | WO | claimed |
| EP-4313104-B1 | DC009 FOR TREATING ACUTE ISCHEMIC STROKE | LUMOSA THERAPEUTICS CO LTD (TW) | 2026-05-13 | — | — | EP | claimed |
| EP-4119139-B1 | ICARITIN FOR USE IN THE TREATMENT OF A BLEEDING DISORDER CAUSED BY PLATELET DYSFUNCTION | LUNAN PHARMACEUTICAL GROUP CORP (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| EP-3996700-B1 | TREATMENT OF PATIENTS UNDER ANTIPLATELET MEDICATION EXPERIENCING BLEEDING | FAELKER KNUT (SE) | 2026-04-29 | — | — | EP | claimed |
| US-5753702-A | INHIBITORS OF NEUTROPHIL ADHESION, ANTIINFLAMMATORY | UNIVERSITY OF VERMONT (US) | 1998-05-19 | — | — | US | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1998004259-A1 | ANTITHROMBOTIC AND ANTIATHEROGENIC PHARMACEUTICAL COMPOSITION INCLUDING A THIENOPYRIDINE DERIVATIVE AND AN HMG-CoA-REDUCTASE INHIBITOR | SANOFI (FR) | 1998-02-05 | — | — | WO | claimed |
| WO-1997044024-A1 | NOVEL ARACHIDONIC ACID METABOLITE, 16-HETE | UNIVERSITY OF VERMONT (US) | 1997-11-27 | — | — | WO | claimed |
| WO-1997029753-A1 | NEW ASSOCIATIONS OF ACTIVE PRINCIPLES CONTAINING CLOPIDOGREL AND AN ANTITHROMBOTIC AGENT | SANOFI (FR) | 1997-08-21 | — | — | WO | claimed |
| WO-1996038136-A1 | LOCALIZED USE OF NITRIC OXIDE-ADDUCTS TO PREVENT INTERNAL TISSUE DAMAGE | NITROMED INC (US) | 1996-12-05 | — | — | WO | claimed |
| US-5576328-A | CLOPIDOGREL | ELF SANOFI (FR) | 1996-11-19 | — | — | US | claimed |
| WO-1996035416-A1 | LOCALIZED USE OF NITRIC OXIDEADDUCTS TO PREVENT INTERNAL TISSUE DAMAGE | NITROMED, INC. (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0724436-A1 | USE OF NITRIC OXIDE-ADDUCTS TO PREVENT THROMBOSIS ON ARTIFICIAL AND VASCULAR SURFACES | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995007691-A1 | USE OF NITRIC OXIDE-ADDUCTS TO PREVENT THROMBOSIS ON ARTIFICIAL AND VASCULAR SURFACES | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1995-03-23 | — | — | WO | claimed |